Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Poletti (Forlì, Italy), C. Albera (Turin, Italy), S. Harari (Milan, Italy), A. Pesci (Monza, Italy), A. Ori (Modena, Italy), G. Crespi (Milan, Italy), B. Campolo (Milan, Italy), C. Vancheri (Catania, Italy). Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study. 1855

Member's Comments

No comment yet.

Related content which might interest you: Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018 Year: 2019 Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials Source: International Congress 2017 – COPD management: new findings from large studies Year: 2017 The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017 ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial Source: International Congress 2018 – Primary care management of respiratory conditions Year: 2018 Validation of the codex index in patients with COPD enrolled in randomized clinical trials: A post-hoc analysis of the trilogy, trinity and tribute studies. Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a post hoc analysis from a randomised controlled trial Source: Eur Respir J, 52 (2) 1800555; 10.1183/13993003.00555-2018 Year: 2018 Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial Source: ERJ Open Res, 4 (4) 00136-2018; 10.1183/23120541.00136-2018 Year: 2018 Post hoc analysis of a randomised controlled trial: effect of vitamin D supplementation on circulating levels of desmosine in COPD Source: ERJ Open Res, 6 (4) 00128-2019; 10.1183/23120541.00128-2019 Year: 2020 Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial Source: ERJ Open Res, 7 (4) 00418-2021; 10.1183/23120541.00418-2021 Year: 2021 Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Clinical significance of serum SP-D as a biomarker for antifibrotics in idiopathic pulmonary fibrosis (IPF): Post hoc analysis of a phase 3 trial of pirfenidone in Japan Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Smartphone-enabled detection of COugh in COvid-19 (COCO) – preliminary analysis of an exploratory, observational cohort study Source: Virtual Congress 2021 – E-health for COVID-19 Year: 2021 Head-to-head analysis of IGRAs and skin-testing in immunocompromised patients: Interim analysis of a multicenter TBNET study Source: Annual Congress 2011 - What is new in tuberculosis immunodiagnosis? Year: 2011 Correlation between clinic and remote FEV1 and FeNO measurements; post hoc analysis of the INCONTRO study Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020 Head-to-head analysis of IGRAs and skin-testing in immunocompromised patients: Interim analysis of a multicenter TBNET study Source: Annual Congress 2010 - Interferon-gamma releases assays (IGRAs) for the diagnosis of tuberculosis: what is the role? Year: 2010 Economic impact of IPF exacerbations in Spain: prospective, observational, multicentric study (OASIS study) Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021